


CTEP

Chemical Properties

CAS No. : 871362-31-1
Formula: C₁₉H₁₃ClF₃N₃O
Molecular Weight: 391.77
Appearance: no data available
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	CTEP (RO 4956371) (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC ₅₀ of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.
Targets(IC ₅₀)	GluR
In vitro	CTEP inhibits quisqualate-induced Ca ²⁺ mobilization with an IC ₅₀ of 11.4 nM and [3H]IP accumulation with an IC ₅₀ of 6.4 nM in HEK293 cells stably expressing human mGlu5. CTEP inhibits the constitutive activity of human mGlu5 by approximately 50% with an IC ₅₀ of 40.1 nM in HEK293 cells stably expressing human mGlu5. [1]
In vivo	CTEP exhibits significant efficacy at doses of 0.1 mg/kg and 0.3 mg/kg for treating anxiety in mice and enhances drinking behavior in the Vogel conflict drinking test at doses of 0.3 mg/kg and 1.0 mg/kg in rats, showing no effect at lower doses. The compound demonstrates an oral half-life of 18 hours, with a brain/plasma (B/P) ratio of 2.6 in mice, indicating its penetration and persistence in brain tissue. When administered orally to adult C57BL/6 mice as a microsuspension in saline/Tween, CTEP is rapidly absorbed, reaching near-maximal levels about 30 minutes post-dosing. Chronic dosing of 2 mg/kg orally every 48 hours for two months in adult mice ensures a minimal brain concentration of 240 ng/g. CTEP effectively displaces [3H]ABP688 from mGlu5 receptors in the mouse brain, with a 50% displacement achieved at an average brain concentration of 77.5 ng/g. At a regimen of 2 mg/kg orally twice daily, CTEP maintains continuous mGlu5 receptor engagement over 48 hours. Additionally, CTEP treatment at 2 mg/kg orally corrects hippocampal dysfunction, excessive protein synthesis, and audiogenic seizures in Fmr1 knockout mice, showcasing its potential in addressing a range of neurological conditions.
Kinase Assay	For all filtration radioligand binding assays, membrane preparations expressing the target receptors or receptor combinations are resuspended in radioligand binding buffer (15 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 1.25 mM CaCl ₂ , and 1.25 mM MgCl ₂ , pH 7.4), and the membrane suspension is mixed with the appropriate concentrations of radioligand and nonlabeled drugs in 96-well plates in a total volume of 200 µL and incubated for 60 min at the appropriate temperature. At the end of the incubation, membranes are filtered onto Whatman Unifilter preincubated with 0.1% polyethyleneimine in ish buffer (50 mM Tris-HCl, pH 7.4) with a Filtermate 196 harvester and washed three times with ice-cold ish buffer. Radioactivity captured on the filter is quantified on a Topcount microplate scintillation counter with quenching correction

after the addition of 45 µL of MicroScint 40 per well and shaking for 20 min. The concentration of membranes and incubation time is determined for each assay in pilot experiments.

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 10 mg/mL (25.52 mM), DMSO: 72 mg/mL (183.8 mM), < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5525 mL	12.7626 mL	25.5252 mL
5 mM	0.5105 mL	2.5525 mL	5.105 mL
10 mM	0.2553 mL	1.2763 mL	2.5525 mL
50 mM	0.0511 mL	0.2553 mL	0.5105 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lindemann L, et al. J Pharmacol Exp Ther, 2011, 339(2), 474-486.

Michalon A, et al. Neuron, 2012, 74(1), 49-56.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E-mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481